A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma

Martin Dreyling, Constantine S. Tam, Michael Wang, Stephen D. Smith, Marco Ladetto, Hui-Qiang Huang, William Novotny, Melannie Co, Alfredo Romano, Eric Holmgren, Jane Huang, Steven Le Gouill

Research output: Contribution to journalArticlepeer-review

Abstract

Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens and stem cell transplant, leaving them with limited options. Targeted therapies, including Bruton tyrosine kinase inhibitors, are an effective treatment strategy in mantle cell lymphoma. Zanubrutinib is a potent next-generation Bruton tyrosine kinase inhibitor that has demonstrated complete and sustained Bruton tyrosine kinase occupancy, minimal off-target effects and favorable pharmacokinetic/pharmacodynamic properties. Described herein is an ongoing Phase III study comparing the efficacy and safety of zanubrutinib plus rituximab followed by zanubrutinib monotherapy versus bendamustine plus rituximab followed by observation in transplant-ineligible patients with previously untreated mantle cell lymphoma. Clinical Trial Registration: NCT04002297 (ClinicalTrials.gov.

Original languageEnglish (US)
Pages (from-to)255-262
Number of pages8
JournalFuture Oncology
Volume17
Issue number3
DOIs
StatePublished - Jan 2021

Keywords

  • Bruton tyrosine kinase
  • BTK inhibitor
  • clinical trial
  • mantle cell lymphoma
  • zanubrutinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma'. Together they form a unique fingerprint.

Cite this